It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

"We have seen an alarming rise in diabetes over the past three decades, which reflects the increase in obesity, compounded by the impacts of the marketing of unhealthy food, a lack of physical ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs ...

The decision by Novo Nordisk to discontinue the insulin pens will force patients to revert to syringes, complicating diabetes care for millions of people.

Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

Insulin production is dominated by the US’s Eli Lilly and Europe’s Sanofi and Novo Nordisk. All three pharmaceutical ...

We need a health system that not only provides medication but also encourages a healthy lifestyle. Group empowerment, digital ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...